News About: Pharm. Industry
Taksen takes on other NSAIDs
Green Cross Corporation is enjoying brisk sales of its non-steroidal anti-inflammatory drug (NSAID), Taksen.
Sales of GCC’s Taksen reached over 3 billion won since its release in November 2007, making it one of th...
1,133 drugs registered in KPIC in first half
The Korea Pharmaceutical Information Center (KPIC) said on July 13 that a total of 1,133 medicines in the form of solid forms (tablets or capsules) were newly registered to the KPIC in the January-June period, under t...
US Bio association expresses negative response on biosimilars
The US Senate introduced a bipartisan bill on March 26, 2009, which establishes a regulatory pathway for approval of biosimilars.
A key provision in the Senate bill is to establish five years of market exclusivity ...
Short-sighted push-up sales practice to hit pharmaceutical firms
There are mounting voices in the local pharmaceutical industry that Korean drug makers will no longer be dependent on ‘forced sales’ of OTC products to achieve their sales target.
Market experts pointed out that su...
Dongbang eyes ginkgo business
Dongbang Pharm has recently re-initiated its business of Ginkomin (gingko biloba extract), since its discontinuation for 18 years.
The company said it will make this year a year for second take-off by concentrating...
KFDA mulls donation of talc-tainted medicines with asbestos
The Korea Food and Administration is likely to permit the donation of about 1,000 drugs, which were confirmed to have used talc or talcum powders with asbestos, to foreign countries.
Sources say there is a big poss...
Samsung Electronics to promote biosimilar business
Samsung Electronics Co is poised to enter the global bio-similar market together with local biotech firms backed by the government.
The government announced on July 8 that it would inject 155 billion won ($121 mill...
Yuhan set to export Revanex to Indian market
Yuhan Corporation said on July 8 that it signed a licensing agreement with India based Zydus Cadila over the export of its novel acid pump antagonist Revanex (revaprazan) into Indian market.
Under the agreement, Yu...
Green Cross first NDA approval for anticancer drug from US FDA
Green Cross Corporation said on July 7 it received the first new drug approval (NDA) from US Food and Drug Administation for greenstatin, an investigational anticancer drug that inhibits the formation of new blood ves...
Korea’s leading drug makers depend on flagship products
The nation’s leading pharmaceutical firms have been heavily dependent on their top-selling medicines for sales boost, according to Yakup Shinmoon.
The trade paper said that revenues of eight drugs in Dong-A Pharm a...
